Selecta Biosciences, Inc. (NASDAQ:SELB) CFO David Siewers sold 16,424 shares of the company’s stock in a transaction on Wednesday, September 20th. The stock was sold at an average price of $20.00, for a total transaction of $328,480.00. Following the completion of the sale, the chief financial officer now owns 2,194 shares of the company’s stock, valued at $43,880. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

David Siewers also recently made the following trade(s):

  • On Friday, June 30th, David Siewers sold 7,420 shares of Selecta Biosciences stock. The stock was sold at an average price of $20.00, for a total transaction of $148,400.00.
  • On Thursday, June 29th, David Siewers sold 9,652 shares of Selecta Biosciences stock. The stock was sold at an average price of $20.00, for a total transaction of $193,040.00.
  • On Monday, June 26th, David Siewers sold 6,886 shares of Selecta Biosciences stock. The stock was sold at an average price of $20.00, for a total transaction of $137,720.00.

Selecta Biosciences, Inc. (SELB) traded down 2.89% on Friday, reaching $19.17. 255,405 shares of the company’s stock were exchanged. The firm’s 50-day moving average is $17.80 and its 200-day moving average is $17.80. The firm’s market cap is $423.16 million. Selecta Biosciences, Inc. has a 12 month low of $11.95 and a 12 month high of $28.00.

Selecta Biosciences (NASDAQ:SELB) last released its earnings results on Friday, August 11th. The company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.01. Selecta Biosciences had a negative net margin of 1,277.76% and a negative return on equity of 88.31%. The business had revenue of $0.03 million during the quarter. On average, equities analysts forecast that Selecta Biosciences, Inc. will post ($3.17) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/09/22/david-siewers-sells-16424-shares-of-selecta-biosciences-inc-selb-stock.html.

Institutional investors and hedge funds have recently made changes to their positions in the company. Nationwide Fund Advisors grew its position in shares of Selecta Biosciences by 224.5% in the 2nd quarter. Nationwide Fund Advisors now owns 6,593 shares of the company’s stock valued at $131,000 after acquiring an additional 4,561 shares during the period. The Manufacturers Life Insurance Company grew its position in shares of Selecta Biosciences by 827.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,254 shares of the company’s stock valued at $224,000 after acquiring an additional 10,040 shares during the period. Rhumbline Advisers bought a new position in shares of Selecta Biosciences in the 2nd quarter valued at about $239,000. New York State Common Retirement Fund grew its position in shares of Selecta Biosciences by 184.0% in the 2nd quarter. New York State Common Retirement Fund now owns 12,500 shares of the company’s stock valued at $248,000 after acquiring an additional 8,099 shares during the period. Finally, Bank of New York Mellon Corp bought a new position in shares of Selecta Biosciences in the 1st quarter valued at about $211,000. 53.53% of the stock is owned by institutional investors.

A number of research analysts have weighed in on SELB shares. Canaccord Genuity set a $25.00 target price on shares of Selecta Biosciences and gave the stock a “buy” rating in a research report on Wednesday, July 26th. Zacks Investment Research raised shares of Selecta Biosciences from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th. Finally, ValuEngine raised shares of Selecta Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, June 30th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $26.00.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.

Insider Buying and Selling by Quarter for Selecta Biosciences (NASDAQ:SELB)

Receive News & Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.